Diseases of the Nervous System, Phase II

Study of Safety and of the Mechanism of BLZ945 in ALS Patients

Volunteers
Health Professionals

What is the purpose of this trial?

This is an open label study to evaluate safety, tolerability and brain microglia response in participants with ALS following multiple doses of BLZ945.

Trial with
Novartis Pharmaceuticals
Ages
18 years - 75 years
Gender
Both

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Kristen Torres

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Huned Patwa, MD
Professor of Neurology; Chief, VA Neurology Service; Chief, Division of Neuromuscular Medicine; Co-Director, MDA Clinic

Sub-Investigators

Last Updated
02/02/2024
Study HIC
#2000026495